<DOC>
	<DOCNO>NCT01199146</DOCNO>
	<brief_summary>This phase II , open label , single center study evaluate efficacy abiraterone acetate ( CB7630 ) administer patient castrate resistant prostate cancer experience disease progression ketoconazole . It hypothesize abiraterone active patient experience disease progression ketoconazole</brief_summary>
	<brief_title>Abiraterone Post Ketoconazole Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Ketoconazole</mesh_term>
	<mesh_term>Abiraterone Acetate</mesh_term>
	<criteria>Histologically confirm adenocarcinoma prostate Prior therapy ketoconazole castration resistant prostate cancer . Patients demonstrate evidence progression ( see definition ) ketoconazole evidence grade 3/4 toxicity ketoconazole . 1 . Ketoconazole must administer &gt; 28 day 2 . At least 27 day must elapse since last ketoconazole dose first dose abiraterone acetate No prior therapy chemotherapy metastatic prostate cancer Metastatic disease base positive bone scan objective imaging CT scan Ongoing gonadal androgen deprivation therapy LHRH analogues orchiectomy . Patients , orchiectomy , must maintain effective LHRH analogue therapy duration trial Testosterone &lt; 50 ng/dL Progressive disease androgen deprivation : PSA evidence progressive prostate cancer consist PSA level least 2 ng/ml rise least 2 successive occasion , least 2 week apart Patients receive antiandrogen part primary androgen ablation must demonstrate disease progression follow discontinuation antiandrogen ECOG Performance Status 01 Age &gt; 18 year able comply protocol requirement Serum Creatinine ≤1.5 x ULN Serum potassium &gt; 3.5mmol/L Bilirubin ≤1.5x ULN AST ALT ≤2.5 x ULN Life expectancy &gt; 12 week Therapy hormonal therapy , include dose megestrol acetate ( Megace ) , finasteride ( Proscar ) , dutasteride ( Avodart ) herbal product know decrease PSA level ( e.g. , Saw Palmetto PCSPES ) , systemic corticosteroid within 4 week prior first dose study drug Therapy supplement complementary medicines/botanicals within 4 week first dose study drug , except combination follow ; conventional multivitamin supplement , Selenium , Lycopene Soy supplement Prior radiation therapy complete &lt; 4 week prior enrollment Prior chemotherapy castration resistant prostate cancer . Patients receive chemotherapy early stage prostate cancer ( e.g . part neoadjuvant adjuvant trial ) malignancy eligible provide &gt; 1 year pass since administration last chemotherapy dose . Hemoglobin ≤9.0 g/dL Any `` currently active '' second malignancy , nonmelanoma skin cancer Patients consider `` currently active '' malignancy , complete therapy consider physician least less 30 % risk relapse next 3 month Blood pressure control despite &gt; 2 oral agent ( SBP &gt; 160 DBP &gt; 90 three reading within screen period ) Serum K+ &lt; 3.5 mmoL/L one reading within screen period NYHA Class II , NYHA Class III IV Congestive Heart Failure Myocardial infarction within 6 month prior first dose study drug Serious intercurrent infection nonmalignant medical illness uncontrolled Concurrent therapy drug metabolize substrate CYP1A2 , CYP2D6 , CYP2C19 consider investigator pose risk drug drug interaction</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2015</verification_date>
	<keyword>Abiraterone acetate</keyword>
</DOC>